Combination vaccine
Showing 1 - 25 of >10,000
Healthy Volunteers Trial in Dhaka (ShigETEC live, attenuated, oral vaccine, Placebo)
Not yet recruiting
- Healthy Volunteers
- ShigETEC live, attenuated, oral vaccine
- Placebo
-
Dhaka, BangladeshInternational Centre for Diarrhoeal Diseases Research, Banglades
Aug 3, 2023
Diarrheal Disease, Infectious, Gastrointestinal Disease, Reactive Arthritis Trial in Debrecen (ShigETEC live, attenuated, oral
Completed
- Diarrheal Disease, Infectious
- +2 more
- ShigETEC live, attenuated, oral vaccine
- Placebo
-
Debrecen, HungaryDebreceni Egyetem, Klinikai Központ, Belgyógyászati Klinika, Kli
Jun 3, 2022
Safety?Immunogenicity Trial in Mianyang City (A single-center and single-arm design was used to evaluate the safety and
Recruiting
- Safety、Immunogenicity
- A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
-
Mianyang City, Sichuan, ChinaSantai County Center for Disease Control and Prevention
Jan 8, 2022
Polio Trial (polio vaccines: nOPV2, bOPV, IPV)
Not yet recruiting
- Polio
- polio vaccines: nOPV2, bOPV, IPV
- (no location specified)
Nov 2, 2023
Advanced Malignant Solid Tumors Trial (Neoantigen mRNA Personalised Cancer vaccine)
Not yet recruiting
- Advanced Malignant Solid Tumors
- Neoantigen mRNA Personalised Cancer vaccine
- (no location specified)
Jul 16, 2023
Posto Perative Hepatocellular Carcinoma Trial (Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I
Not yet recruiting
- Posto Perative Hepatocellular Carcinoma
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- (no location specified)
Feb 27, 2023
Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1
Not yet recruiting
- Metastatic Colorectal Cancer
- Retifanlimab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 4, 2023
Colo-rectal Cancer Trial (biological, drug, procedure)
Not yet recruiting
- Colo-rectal Cancer
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- +8 more
- (no location specified)
Aug 28, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Low Grade Glioma of Brain Trial in Durham (PEPIDH1M vaccine + vorasidenib)
Not yet recruiting
- Low Grade Glioma of Brain
- PEPIDH1M vaccine + vorasidenib
-
Durham, North CarolinaDuke University Medical Center
Nov 2, 2022
Healthy Trial in Buenos Aires (RSVpreF+qIRV, qIRV, RSVpreF)
Recruiting
- Healthy
- RSVpreF+qIRV
- +3 more
-
Buenos Aires, ArgentinaHospital Militar Central Cirujano Mayor Dr. Cosme Argerich
Mar 27, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01 in combination with standard adjuvant therapy)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01 in combination with standard adjuvant therapy
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Poliomyelitis Trial in Dhaka (Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2),
Not yet recruiting
- Poliomyelitis
- Novel oral poliomyelitis vaccine type 1 (nOPV1)
- +3 more
-
Dhaka, BangladeshInternational Centre for Diarrhoeal Disease Research
Nov 14, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Ovarian Carcinoma Trial (PEP-DC1, OC-DC, PEP-DC2)
Not yet recruiting
- Ovarian Carcinoma
- PEP-DC1
- +3 more
- (no location specified)
Jan 26, 2023
Poliomyelitis Trial (Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant
Recruiting
- Poliomyelitis
- Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)
- +2 more
-
Burlington, VermontUniversity of Vermont Vaccine Testing Center at the Larner Colle
Sep 2, 2022
Neuroblastoma Trial in New York (dietary supplement, drug, biological)
Recruiting
- Neuroblastoma
- β-glucan
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 5, 2022
Metastatic Prostate Cancer, Prostate Cancer, Prostate Tumor Trial run by the NCI (M7824, N-803, MVA-BN-Brachyury)
Recruiting
- Metastatic Prostate Cancer
- +4 more
- M7824
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Castration Resistant Prostate Cancer Trial run by the National Cancer Institute (NCI) (Bintrafusp alfa, N-803, BN-Brachyury)
Not yet recruiting
- Castration Resistant Prostate Cancer
- Bintrafusp alfa
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Metastatic Hormone-Sensitive Prostate Cancer Trial in Saint Louis (biological, drug, device, procedure)
Completed
- Metastatic Hormone-Sensitive Prostate Cancer
- PROSTVAC-V
- +9 more
-
Saint Louis, MissouriWashington University School of Medicine
Aug 3, 2022
Unresectable or Metastatic Melanoma Trial in Australia, United States (Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4
Terminated
- Unresectable or Metastatic Melanoma
- Ipilimumab
- +3 more
-
New York, New York
- +4 more
Oct 3, 2022
Carcinoma, Renal Cell Trial in Pittsburgh (Autologous alpha-DC1/TBVA vaccine, Cabozantinib)
Not yet recruiting
- Carcinoma, Renal Cell
- Autologous alpha-DC1/TBVA vaccine
- Cabozantinib
-
Pittsburgh, PennsylvaniaUPMC Department of Urology
Jan 5, 2023
Neuroblastoma, Pediatric Solid Tumor Trial in Boston (procedure, biological, drug)
Recruiting
- Neuroblastoma
- Pediatric Solid Tumor
- Tissue collection
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 17, 2022
Head Neck Cancer, Head and Neck Tumors Trial run by the NCI (M7824, N803, TriAd vaccine)
Active, not recruiting
- Head and Neck Cancer
- Head and Neck Neoplasms
- M7824
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Not yet recruiting
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- +3 more
- PD-L1/IDO Peptide Vaccine
- Pembrolizumab
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Apr 24, 2023